---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-002428"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2026-01-15T23:59:59+00:00"
generated_at: "2026-05-16T10:08:14.853937+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K

## Summary
- Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.
- Annual base salary $350,000; $50,000 deferred until equity financing ≥$3M, termination, or change of control.
- Annual cash bonus target 35% of base salary based on Board-set goals.
- Change-of-control bonus: 3% of enterprise value if ≥$5M.
- Severance: 6 months base plus bonus upon termination without cause or good reason; equity acceleration provisions.

## SEC filing metadata
- accession: 0001493152-26-002428
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2026-01-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000149315226002428/0001493152-26-002428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000149315226002428/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-002428
- JSON: https://secwatch.observer/filing/0001493152-26-002428.json
- Plain text: https://secwatch.observer/filing/0001493152-26-002428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.